In this project, ANGLE’s research team will use the Parsortix system to collect cancer cells from the blood of cancer patients. These cells will then be studied and compared with tissue samples from the same patients using Myriad Genetics’ established testing methods. The goal is to replace traditional tissue biopsies with a simpler blood test, making it easier and faster for patients to get important genetic information about their cancer. This could lead to better and quicker treatment decisions. Andrew Newland, CEO of ANGLE, said: ‘We’re excited to work with Myriad Genetics to adapt their tests for a blood-based approach using cancer cells captured by Parsortix. This partnership could greatly improve cancer care by making key genetic data more accessible.’ While full details of the agreement are private, the companies aim to expand the use of liquid biopsies in personalized cancer treatment. ANGLE’s Parsortix technology is already FDA-approved for collecting cancer cells from blood, and over 110 research studies support its effectiveness.